The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

“In contrast, branded specialty products represent more than 50% of our clients’ total drug spend and are entirely ignored by the FTC.” Express Scripts, meanwhile, declared in a statement th ...

Eagan-based Prime Therapeutics has been ordered to pay $10 million in damages after federal arbitration found it engaged in ...

Pharmacy benefit managers overcharged for specialty generic medications — in many cases by hundreds and thousands of percent ...

Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.

"Given the fact that there are states, counties, cities, school districts, pension funds, and other plaintiffs from all over ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

The FTC analyzed data for 51 specialty generic drugs dispensed from 2017-2022 for patients with commercial insurance or Medicare Part D plans managed by CVS Caremark, Express Scripts and OptumRx.

On September 20, the FTC filed a lawsuit against the three largest prescription drug benefit managers (PBMs)—Caremark, Express Scripts (ESI), and United Health's OptumRx "for engaging in ...

Specifically, the FTC’s first report found Caremark, Express Scripts and Optum Rx were prioritizing access to high-cost drugs in return for larger discounts from drugmakers and giving their own ...

The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...